1. Volume 79, Issue 4, Pages 393-403 (February 2011)
Nephrolithiasis-associated bone disease: pathogenesis and treatment options 
Khashayar Sakhaee, Naim M. Maalouf, Rajiv Kumar, Andreas Pasch, Orson W. Moe 
Kidney International 
Volume 79, Issue 4, Pages (February 2011)
DOI: /ki
Copyright © 2011 International Society of Nephrology Terms and Conditions

2. Figure 1
Cumulative incidence of vertebral fracture among Rochester, Minnesota, residents following an initial episode of symptomatic nephrolithiasis. The solid line indicates observed. The dashed line indicates expected. Figure reprinted with permission by Melton et al.3
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

3. Figure 2
Mechanisms of action of potential therapeutic agents. ECF, extracellular fluid; =inhibitory role; =stimulatory role.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

4. Figure 3
The effect of thiazide/indapamide and K-Cit on BMD of the L2–L4 spine, femoral neck, and radial shaft of hypercalciuric kidney stone formers. Data are expressed as percentage of normal, matched for age and gender (Z-score). **Indicates P=0.001, †indicates P< Bars above the blocks represent mean±s.d. Figure reprinted with permission by Pak et al.136 BMD, bone mineral density; K-Cit, potassium citrate.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions